Avadel Pharmaceuticals plc Ordinary Share
AVDLAvadel Pharmaceuticals plc is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for the treatment of chronic diseases, primarily targeting sleep and neurological disorders. The company emphasizes leveraging its proprietary drug delivery technologies to improve patient outcomes and address unmet medical needs.
Company News
State Street Global Advisors & Affiliates disclosed a purchase of 621 ordinary shares in Avadel Pharmaceuticals plc on January 15, 2026, bringing their total holding to 2,298,069 shares representing 2.36% of the company. The disclosure was filed under Irish Takeover Panel Rule 8.3.
Avadel Pharmaceuticals shareholders have approved the proposed acquisition by Alkermes plc through a scheme of arrangement. The approval was overwhelming, with 97.41% of votes cast in favor at the scheme meeting and 96.53% approval at the extraordinary general meeting. The transaction is expected to proceed pending satisfaction of remaining condi...
State Street Global Advisors & Affiliates disclosed a dealing in Avadel Pharmaceuticals plc on December 23, 2025, purchasing 2,433 shares at $21.54 per unit while selling 263 shares at the same price. The entity now holds 2,292,882 shares representing 2.35% of the company's ordinary shares.
Law firm Halper Sadeh LLC is investigating potential securities law violations and fiduciary duty breaches for several companies involved in merger and acquisition transactions.
Avadel Pharmaceuticals announced the mailing of a proxy statement regarding its proposed acquisition by Alkermes, with scheme and extraordinary general meetings scheduled for January 12, 2026, to vote on the transaction.
